Atea Pharmaceuticals Doses First Patient in Phase 3 COVID-19 Trial

Boston-based Atea Pharmaceuticals has begun dosing patients in a phase 3 global trial of its oral antiviral AT-527 for patients with mild-to-moderate COVID-19.

The study aims to enroll an estimated 1,400 nonhospitalized adults and adolescents at a large number of clinical sites worldwide, the company said.

AT-527, which is based on Atea’s nucleotide prodrug platform, works by inhibiting replication of the SARS-CoV-2 virus. It is being co-developed by Roche.